DMHCA

N,N-dimethyl-3β-hydroxy-cholenamide (DMHCA) is a potent steroidal liver X receptor (LXR) ligand in vitro and in vivo. It is used to treat atherosclerosis.[1]

DMHCA has been used as LXR activator to treat retinal endothelial cells in order to activate the sirtuin 1- liver X receptors (SIRT1-LXR) pathway.[2]

It may be used as 3β-hydroxysterol-Δ²⁴-reductase (DHCR24) inhibitor.[3][4]

N,N-dimethyl-3β-hydroxycholenamide (DHMCA) halts cholesterol biosynthesis by inhibiting 3β-hydroxysterol-Δ²⁴-reductase (DHCR24) enzyme. It may serve as a therapeutic agent for treating atherosclerosis,[3] age-related macular degeneration and diabetic retinopathy.[4]

DMHCA (N,N-dimethyl-3β-hydroxycholenamide) is a synthetic oxysterol and is an agonist for liver X receptors (LXR).[5] It promotes cholesterol transport, expression of adenosine triphosphate (ATP) binding cassette transporters. DMHCA suppresses the proinflammatory cytokines stimulation, induced by oxysterol.[6]

5 mL Amber Glass Screw Cap Vial (700125P-5mg)

Avanti Research is a trademark of Avanti Polar Lipids, LLC